<?xml version="1.0" encoding="UTF-8"?>
<ref id="B59-molecules-25-00942">
 <label>59.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Vernazza</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Pozniak</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Weil</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Pulik</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Cooper</surname>
    <given-names>D.A.</given-names>
   </name>
   <name>
    <surname>Kaplan</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Lazzarin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Valdez</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Goodrich</surname>
    <given-names>J.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1 infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase IIb trial</article-title>
  <source>J. Acquir. Immune Defic. Syndr.</source>
  <year>2013</year>
  <volume>62</volume>
  <fpage>171</fpage>
  <lpage>179</lpage>
  <pub-id pub-id-type="doi">10.1097/QAI.0b013e31827a2ba2</pub-id>
  <pub-id pub-id-type="pmid">23328090</pub-id>
 </element-citation>
</ref>
